TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent.~* MEA112997 Study Participation: Received at least 2 doses of double-blind investigational product during the MEA112997 trial.~* MEA112997 Treatment Assignment: If the subject received mepolizumab, they must have had a positive risk: benefit ratio.~* Currently being treated with a controller medication and the subject has been on a controller medication for the past 12 weeks.~* Male or Eligible Female Subjects. To be eligible for entry into the study, females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control for the duration of the trial and for 4 months after the last study drug administration.~Exclusion Criteria:~* Hypersensitivity related to mepolizumab.~* Clinically significant change in health status since completing participation in the MEA112997 trial.~* A current malignancy or previous history of cancer in remission for less than 12 months prior to screening.~* For those subjects who had a SAE in MEA112997 that was assessed as possibly related to mepolizumab by the investigator.~* Subjects who are pregnant or breastfeeding. Subjects should not be enrolled if they plan to become pregnant during the time of study participation.~* Screening ECG which has a clinically significant abnormality.~* Received Xolair (omalizumab) within the past 130 days.~* Participated in a clinical trial within the past 30 days or have received investigational medication within five terminal half-lives of Screen Visit, whichever is longer.~* Current smokers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mepolizumab (Type: EXPERIMENTAL): Subjects will receive 100 mg of mepolizumab (in 1ml polypropylene syringe) injected subcutaneously (SC) approximately every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chinese T2D patients who are inadequate controlled (6.5 %\< HbA1C ≤9%) by metformin (≥750mg/d but ≤1000mg/d, ≥12 weeks),~Exclusion Criteria:~* Type 1 diabetes and secondary diabetes~* Acute metabolic diabetic complications within the past 3 months.~* Acute infections which may influence glucose level.~* Evidence of significant chronic diabetic complications,~* Clinically significant renal impairment and hepatic impairment patients, including history of cirrhosis or chronic hepatitis,~* FPG \> 270 mg/dl (15 mmol/l)~* Any of the following disease within the past 6 months: myocardial infarction (MI); coronary artery bypass surgery or percutaneous coronary intervention; unstable angina or stroke; Congestive heart failure (CHF)~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- metformin up titration (Type: ACTIVE_COMPARATOR): metformin 500 mg bid will be up titrated (total daily dose up to 2000 mg)
- vildagliptin add on to metformin (Type: EXPERIMENTAL): Vildagliptin 50 mg twice daily + Metformin 500mg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multi-Center Study of New Medications to Treat Vaginal Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of vaginal infection that is confirmed by laboratory testing and:~* Capable of providing written informed consent or assent~* Currently not menstruating and not anticipating menses during treatment~* If heterosexually active, subject must be post-menopausal for ≥ 1 year, surgically sterile, or practicing an acceptable form of birth control~* Negative pregnancy test~* Other criteria as identified in the protocol~Exclusion Criteria:~* Other infectious causes of vulvovaginitis~* Subject has recently used, or is expected to require the concomitant use of prohibited medications/products~* Nursing mother~* Use of any investigational drug within 30 days of enrollment~* History of hypersensitivity to any ingredient/component of the formulations~* Other criteria as identified in the protocol

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Terconazole vaginal gel (Type: ACTIVE_COMPARATOR): One applicator full at bedtime
- Gel vehicle (Type: PLACEBO_COMPARATOR): One applicator full at bedtime

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing unilateral total hip arthroplasty~Exclusion Criteria:~* Subjects with risks of hemorrhage~* Subjects with thromboembolic risks~* Subjects who weigh less than 40 kg~* Subjects who are pregnant or suspect pregnancy, or subjects who want to become pregnant

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- DU-176b (Type: EXPERIMENTAL): DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery.
- enoxaparin sodium (Type: ACTIVE_COMPARATOR): enoxaparin sodium 20mg(=2000IU)/0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of non-infectious uveitis (pan, anterior, intermediate and posterior)~* Diagnosis of macular edema associated with non-infectious uveitis (retinal thickness ≥ 300 microns)~* Visual Acuity score of ≥ 5 letters read (20/800 Snellen equivalent) and ≤ 70 letters read (20/40 Snellen equivalent), in the study eye~Exclusion Criteria:~* Any active ocular disease or infection in the study eye other than uveitis~* Intraocular pressure \> 22 mmHg or uncontrolled glaucoma in the study eye; subjects are not excluded if IOP ≤ 22 mmHg with no more than 2 IOP lowering medications.~* Any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study~* Any topical ocular corticosteroid in the 10 days prior to baseline; intraocular or periocular corticosteroid injections in the 2 months prior to baseline; an OZURDEX implant in the 6 months prior to baseline; RETISERT or ILUVIEN implant in the 3 years prior to baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 4mg CLS-TA Suprachoriodal Injection (Type: EXPERIMENTAL): Suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
- Sham Procedure (Type: SHAM_COMPARATOR): Matching suprachoroidal syringe with sham procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of 5LGr to Treat Tic Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* \>1 year history of diagnosed tic disorder;~* age:5-18 yrs;~* YGTSS score\>=30 at baseline.~Exclusion Criteria:~* Diagnosed with hyperactivity disorder,epilepsy,chorea,autism,obsessive-compulsive disorder,mental retardation,athetosis,Wilson's disease.~* Any indefinite tic disorder or tic disorders caused by medication.~* Participation to other studies.~* Patients with loose stool.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 5LGr, granule and placebo tablet (Type: EXPERIMENTAL): Drug:5LGr; Dosage form:Granule;Strength:5 gram/sack;Mimic Tablet:0 mg/tablet. Dosage: 5LGr Granule: 1 sack, t.i.d. for patients less than 12 yrs,whereas 1.5 sacks, t.i.d. for patients 13-18 yrs.~Mimic tablet:For patients 5-12 yrs: 0.5 tablet, b.i.d for first 2 weeks, then 1 tablet, bid for next 6 weeks; for patients 13-18 yrs: tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.~Duration: 8 weeks.
- tiapride tabletand mimic 5LGr granule (Type: ACTIVE_COMPARATOR): Tiapride are 100 mg scored tablets. Mimic 5LGr granule are preparation that contain no active ingredient, and act as placebo.~Dosage: Tiaptride tablet: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.~Mimic 5LGr Granule:Strength:0 gram/sack.Dosage:1 sack for patients less than 12 yrs,while 1.5 sacks for patients 13-18 yrs.Frequency: T.i.d.~Duration: 8 weeks.
- placebo, granule and tablet (Type: PLACEBO_COMPARATOR): This arm includes mimic preparation of 5LGr granule and tiapride tablets , which doesn't contain active ingredients.~Dosage form: Mimic Granule:Strength:0 gram/sack Dosage:1 sack, t.i.d for patients less than 12 yrs,while 1.5 sacks, t.i.d for patients 13-18 yrs.~Mimic tablet:Strength:0 mg/tablet.For patients 5-12 yrs: 0.5 tablets b.i.d for first 2 weeks, then 1 tablet,b.i.d for next 6 weeks; for patients 13-18 yrs:1 tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.~Duration: 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Premedication With Nebulized Ketamine,Dexmedetomidine Versus Midazolam in Oncologic Preschool Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* physical status I and II, scheduled for bone marrow aspirate and biopsy~Exclusion Criteria:~* known allergy to the studied drugs,~* organ dysfunction,~* cardiac dysrrhythmia and/or congenital heart disease,~* psychotropic medication use and mental retardation

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- nebulized ketamine (Type: ACTIVE_COMPARATOR): patients will be premedicated with nebulized ketamine solution (2 mg/kg)
- nebulized dexmedetomidine (Type: ACTIVE_COMPARATOR): patients will be premedicated with nebulized dexmedetomidine solution (2 μg/kg)
- nebulized midazolam (Type: ACTIVE_COMPARATOR): patients will be premedicated with midazolam (0.2 mg/kg) nebulized solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Indoor, Community, and Advanced Wheelchair Skills in Spinal Cord Injury (SCI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* SCI for at least 1 year (neurologically stable)~* Level of injury: C6 and below who use manual wheelchair as a primary means of mobility~* Able to self-propel wheelchair~* Between the ages of 18-75~* Able to follow simple instructions~Exclusion Criteria:~* Progressive disease (e.g. spinal tumor)~* Extended bedrest for more than 30 days~* Ventilator-dependent~* Any cardiac or respiratory condition that would limit subject's physical performance~* Unstable medical conditions~* Use power wheelchair or scooter as primary means of mobility~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Wheelchair Skills Training Program (Type: OTHER): Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs. The WSP is a set of assessment and training protocols related to wheelchair skills. The WSP includes the Wheelchair Skills Test (WST), the Wheelchair Skills Training Program (WSTP) and related materials.
- Basic Health Education (Type: OTHER): Basic health educational training sessions: Five sessions are held with subjects to provide them additional information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* clinically diagnosed perioral dermatitis associated or not associated with topical steroid use (the periorbital area may also be involved in addition to the perioral region)~* minimum severity score (PODSI) ≥ 4~* age 18 and older~Exclusion Criteria:~* Ongoing use of the following treatments is NOT allowed after the start of study drug:~Oral tetracyclines, oral erythromycin, oral steroids and oral calcineurin inhibitors. All topical treatments of the face, including steroids, calcineurin inhibitors, metronidazole, tetracyclines, erythromycin and emollients (exception: DAC Basiscreme).~* Systemic immunosuppression~* History of malignancy of any organ system, treated or untreated, within the past 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- 1 (Type: EXPERIMENTAL): Pimecrolimus
- 2 (Type: PLACEBO_COMPARATOR): Vehicle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ECOG performance status of 0-1.~* Diagnosis of CLL or SLL that meets IWCLL 2008 criteria.~* Active disease meeting at least 1 of the IWCLL 2008 criteria for requiring treatment.~* Must have received at least one prior therapy for CLL/SLL.~* Considered not appropriate for treatment or retreatment with purine analog based therapy.~* Measurable nodal disease by CT.~* Patients must be able to receive outpatient treatment and laboratory monitoring at the institution that administers study drug for the entire study.~Exclusion Criteria:~* Known CNS lymphoma or leukemia.~* No documentation of cytogenetic and/or FISH in patient records prior to first dose of study drug.~* Any history of Richter's transformation or prolymphocytic leukemia.~* Uncontrolled Autoimmune Hemolytic Anemia (AIHA) or idiopathic thrombocytopenia purpura (ITP).~* Prior exposure to ofatumumab or to ibrutinib.~* Prior autologous transplant within 6 months prior to first dose of study drug.~* Prior allogeneic stem cell transplant within 6 months or with any evidence of active graft versus host disease or requirement for immunosuppressants within 28 days prior to first dose of study drug.~* History of prior malignancy, with the exception of certain skin cancers and malignancies treated with curative intent and with no evidence of active disease for more than 3 years.~* Serologic status reflecting active hepatitis B or C infection.~* Unable to swallow capsules or disease significantly affecting gastrointestinal function.~* Uncontrolled active systemic fungal, bacterial, viral, or other infection.~* History of stroke or intracranial hemorrhage within 6 months prior to the first dose of study drug.~* Requires anticoagulation with warfarin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ofatumumab (Arm A) (Type: ACTIVE_COMPARATOR): An anti-CD20 monoclonal antibody
- ibrutinib (Arm B) (Type: EXPERIMENTAL): A Bruton Tyrosine Kinase Inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Remodulin® in Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~After Fontan procedure, the criteria should be met~1. mPAP greater than 15 mmHg~2. TPG greater than 6 mmHg (exclude the obstruction of cavopulmonary anastomosis)~Exclusion Criteria:~After Fontan surgery :~1. Severe arrhythmia led to low cardiac output~2. Platelets smaller than 50,000\*109/L and obvious bleeding

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Remodulin Injection (Type: EXPERIMENTAL): Drug: Remodulin Injection Dosage:5 ng/kg/min-80ng/kg/min(0.15ml/hr-2.4ml/hr) Frequency: intravenous maintenance increase at a rate of 10ng/kg/min (0.3ml/hr)every 30 minutes Durations:48 hours
- Distilled water group (Type: PLACEBO_COMPARATOR): Drug:distilled water Dosage:0.15ml/hr-2.4ml/hr Frequency:increase at a rate of 0.3ml/hr every 30 minutes Durations:48 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antimicrobial Photodynamic Therapy in Chronic Periodontitis and Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. aged ≥30 years~2. clinically diagnosed with mild to moderate periodontitis~3. self-reported type-2 DM for ≥2 years confirmed by a physician with HbA1c levels ≥6.5%~4. patients who complied with the treatment protocol.~Exclusion Criteria:~(i) pregnancy and lactation (ii) who had taken antibiotics in the previous 3 months (iii) who had undergone periodontal therapy or any decontamination treatment in their oral cavity in the previous 6 months (iv) former/current smokers (v) failure to provide a signed informed consent.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Controlled Type 2 diabetes mellitus (Type: EXPERIMENTAL): None
- Uncontrolled Type 2 diabetes melltius (Type: EXPERIMENTAL): None
- Non-diabetic patients (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provide written informed consent;~* Pregnant women at ≥ 36 weeks 0 days inclusive gestation;~* Women aged 18 years or older;~* Candidate for pharmacological induction of labor;~* Single, live vertex fetus;~* Baseline modified Bishop score ≤ 4;~* Parity ≤ 3 (parity is defined as one or more births live or dead after 24 weeks gestation);~* Body Mass Index (BMI) ≤ 50 at the time of entry to the study.~Exclusion Criteria:~* Women in active labor;~* Presence of uterine or cervical scar or uterine abnormality e.g., bicornate uterus. Biopsies, including cone biopsy of the cervix, are permitted;~* Administration of oxytocin or any cervical ripening or labor inducing agents (including mechanical methods) or a tocolytic drug within 7 days prior to enrollment. Magnesium sulfate is permitted if prescribed as treatment for pre-eclampsia or gestational hypertension;~* Severe pre-eclampsia marked by Hemolytic anemia, Elevated Liver enzymes, Low Platelet count (HELLP) syndrome, other end-organ affliction or Central Nervous System (CNS) findings other than mild headache;~* Fetal malpresentation;~* Diagnosed congenital anomalies, not including polydactyly;~* Any evidence of fetal compromise at baseline (e.g., non-reassuring fetal heart rate pattern or meconium staining);~* Amnioinfusion or other treatment of non-reassuring fetal status at any time prior to the induction attempt;~* Ruptured membranes ≥ 48 hours prior to the start of treatment;~* Suspected chorioamnionitis;~* Fever (oral or aural temperature \> 37.5°C);~* Any condition in which vaginal delivery is contraindicated e.g., placenta previa or any unexplained genital bleeding at any time after 24 weeks during this pregnancy;~* Known or suspected allergy to misoprostol, dinoprostone, other prostaglandins or any of the excipients;~* Any condition urgently requiring delivery;~* Unable to comply with the protocol.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MVI 200 (Type: EXPERIMENTAL): MVI 200 mcg vaginal insert
- Dinoprostone Vaginal Insert (DVI) (Type: ACTIVE_COMPARATOR): 10 mg Dinoprostone vaginal insert

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete